Krishna Polu is the founder of R1 Therapeutics. R1 Therapeutics has raised $78M in total funding. Latest round: Series A.
Krishna Polu is the co-founder and CEO of R1 Therapeutics, a biotechnology company focused on developing a first-in-class therapy for chronic kidney disease patients on dialysis with high phosphate levels. R1 Therapeutics secured an oversubscribed $77.5 million Series A financing and obtained an exclusive global license for AP306 from Alebund Pharmaceuticals. Polu is a nephrologist with over 20 years of experience in the biopharma industry and has advised Abingworth since April.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide